Expression levels of pathological dysregulated neurodegenerative genes of both Alzheimer's and Parkinson's disease were significantly restored by the therapeutic effect of ANAVEX®2-73 (p<0.005)
These findings will facilitate contextualization of upcoming readout of ANAVEX®2-73 Phase 2b/3 Alzheimer's disease clinical trial
static.seekingalpha.com/upl... ANAVEX®2-73 Improved MDS-UPDRS Total Score in Placebo-Controlled Parkinson’s Disease Dementia Phase 2 Study Estimated Difference between Active and Placebo: -14.51 points (p = 0.034) MDS-UPDRS Total Score ANAVEX2-73 high dose -10.98 Placebo 3.53
Content on HealthUnlocked does not replace the relationship between you and doctors or other healthcare professionals nor the advice you receive from them.
Never delay seeking advice or dialling emergency services because of something that you have read on HealthUnlocked.